RECRUITING

Supporting Treatment Access and Recovery Through Linkage and Support

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This 3-year Hybrid Type 1 study will randomize 208 people with co-occurring substance use and mental health disorders (COD) referred from the Worcester Hub. This study seeks to evaluate the effectiveness of MISSION, a multi-component team approach, versus linkage with a Peer Specialist on improving outcomes among individuals with CODs. We expect that individuals receiving MISSION versus linkage only will show greater improvement in treatment engagement, substance use, and mental health outcomes. This study will also concurrently conduct a process evaluation to inform sustainability and future implementation of such interventions.

Official Title

Rigorous Evaluation of Strategies to Prevent Overdose Through Linking People With Illicit Substance Use Disorder to Recovery Support Services

Quick Facts

Study Start:2023-05-24
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05713695

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Are 18 or older;
  2. * Have a COD (1 or more substance use disorders (e.g., alcohol and illicit substances), and a mental health disorder (including depression, anxiety, trauma related disorders, bipolar, and/or schizophrenia);
  3. * Are in the Hub; and
  4. * Are not engaged in other ongoing multi-component treatment for COD with a behavioral health treatment provider or have not seen their provider for at least 3 months.
  1. * We will exclude individuals who are acutely psychotic, acutely suicidal with a plan, or homicidal
  2. * Or with concurrent severe alcohol use disorder or high dose benzodiazepine requiring detoxification.

Contacts and Locations

Study Contact

David Smelson, PsyD
CONTACT
508-713-5420
David.Smelson@umassmed.edu
Paige Shaffer, MPH
CONTACT
978-609-2312
Paige.Shaffer@umassmed.edu

Principal Investigator

David Smelson, PsyD
PRINCIPAL_INVESTIGATOR
University of Massachusetts, Worcester

Study Locations (Sites)

University of Massachusetts Medical School
Worcester, Massachusetts, 01655
United States

Collaborators and Investigators

Sponsor: University of Massachusetts, Worcester

  • David Smelson, PsyD, PRINCIPAL_INVESTIGATOR, University of Massachusetts, Worcester

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-24
Study Completion Date2026-09

Study Record Updates

Study Start Date2023-05-24
Study Completion Date2026-09

Terms related to this study

Keywords Provided by Researchers

  • Co-Occurring Disorders
  • Opioid Overdose
  • Mental Health Disorders
  • Substance Use
  • Medication for Opioid Use Disorder (MOUD)
  • Peer Support
  • Medication Assisted Treatment (MAT)
  • Healthcare Access
  • Social Determinants of Health
  • Coordination of Care
  • Socioecological Model
  • Multi-component Interventions
  • Addiction
  • Equity

Additional Relevant MeSH Terms

  • Mental Health Disorders
  • Substance Use Disorders